Perkenalkan Sukarelawan Ps1 (HUSM)..Effa & Salina...
Rabu, Oktober 31
Assallammualikum dan Salam 1Malaysia
Pusat Sumber Kanser Payudara HUSM akan mengadakan satu seminar kesihatan di DK 8 PPSP USM .Kepada semua yang berminat boleh menghubungi PS1 untuk mendapat keterangan yang selanjutnya.Sokongan anda semua amat kami hargai.
Pusat Sumber Kanser Payudara HUSM akan mengadakan satu seminar kesihatan di DK 8 PPSP USM .Kepada semua yang berminat boleh menghubungi PS1 untuk mendapat keterangan yang selanjutnya.Sokongan anda semua amat kami hargai.
Sayangi Dirimu.....Keluarga...dan Masyarakat.....
Rabu, September 12
Aswt & Salam 1Malaysia..mari kita bersama memahami artikel terbaru ini.....
Mammography Could Reduce Mortality by 50%
September 4, 2012 (Montreal, Quebec) — Regular screening mammography reduces mortality from breast cancer by at least 50% in women 50 to 69 years of age, not by one fifth as estimated by the Canadian Task Force on Preventive Health Care, in the opinion of one public health researcher speaking here at the Union for International Cancer Control World Cancer Congress 2012.
Wilbur Deck, MD, from the National Institute for Excellence in Health and Social Services in Quebec City, Quebec, Canada, took the Canadian Task Force to task for their estimation of the mortality benefit from regular mammography, which he feels is "clearly biased downward" for women 50 to 69 years of age.
In their update of screening recommendations published in 2011, the Canadian Task Force recommends routine screening every 2 to 3 years for women 50 to 69 years of age on the basis of "moderate quality" evidence.
This recommendation is graded as "weak."
"The task force did not do the actual review of the screening studies. They farmed out what I think should be their core competency, which is to analyze the data. It was the group [to whom the review was farmed out] that estimated that the reduction in mortality from breast cancer screening was 21%," Dr. Deck told Medscape Medical News. "Even though a lot of people in those studies were never actually screened, the task force never challenged that number."
As Dr. Deck explained to delegates, there is a large discrepancy between estimates of mortality reduction from mammography, ranging from virtually no benefit to as much as 35%.
Evidence From RCTs
By far the most common evidence used to arrive at these mortality estimates comes from randomized controlled trials (RCTs).
"RCTs show about a 20% mortality reduction [with mammography], but it's important to point out that this estimate is unadjusted for several major factors," Dr. Deck explained.
The first major factor is that some of the studies were initiated in the 1960s, when the technology used to screen for breast cancer was far less advanced than the dedicated mammography equipment used today.
A second is what Dr. Deck called "low contrast" in these screening studies.
"When you do an RCT, you compare those who had a trial intervention to a control group that doesn't get the intervention; in most RCTs, that is approximately true," he said.
However, in breast cancer screening studies, "it is not approximately true because probably less than 50% of participants are getting regular screening," Dr. Deck noted. People in the control group can also decide they might benefit from mammography and go out and get screened, thereby diluting the control group.
"This reduces the contrast [between the 2 groups] and, obviously, it reduces how effective mammography will appear to be," Dr. Deck noted.
The third problem is that breast cancer screening only has an impact over the very long term.
In simulations he himself has done, Dr. Deck calculated that the degree of mortality reduction is underestimated by about half if early mortality data are included in estimates and the data are only followed for about 15 years.
At 10 years, recurrence rates after the initial diagnosis of breast cancer are still high, at approximately 45%, even if a woman has been diagnosed with a small (2 to 3 cm) tumor and only 1 positive node.
In contrast, if a woman has a tumor of 1 to 2 cm and no positive nodes, "the recurrence rate at 10 years is only 17%, so it's pretty important to detect cancer early," Dr. Deck said. Indeed, if stage distribution and prognosis at various stages are used to estimate the mortality reduction from breast cancer related to mammography, "you see reductions of between 50% and 60%," he added.
Similarly, a review of all case–control studies of women who received regular screening and those who did not found a reduction of about 50% in breast cancer mortality with regular screening.
We may be overdoing it in terms of underpromising for mammography.
"It's good to underpromise and overdeliver, but we may be overdoing it in terms of underpromising for mammography," Dr. Deck said. "If you look at RCTs and adjust for participation, contrast, and timing, you arrive at a mortality reduction of 50% to 60%; if you look at stage-distribution estimates, it's about 50% to 60%; and if you look at case–control studies, it's about 50%. These estimates don't take into account probable improvements in mortality based on technological advances. I think groups like the Canadian Task Force are probably doing a disservice to people who are considering whether or not mammography might be useful for them," he explained.
Need to Consider Other Morbidities
Session chair Jean Rousseau, PhD, from the Public Health Institute of Canada, emphasized that older women can have other morbidities that need to be taken into account when considering mammography.
Physicians need to start tailoring screening recommendations to older women on the basis of the presence or absence of potentially important morbidities, he explained. "There are a lot of women in the target age group who are still very healthy and who could benefit from mammography — there is no doubt about this — but women in this age group are more diverse than we tend to think," Dr. Rousseau told Medscape Medical News. "You have to ask if mammography is the most appropriate strategy for women who have important morbidities and we need to consider women more on an individual basis with respect to their needs."
Dr. Deck reports being involved with a breast cancer screening program in Quebec. Dr. Rousseau has disclosed no relevant financial relationships.
Union for International Cancer Control (UICC) World Cancer Congress 2012. Presented August 29, 2012.
Mammography Could Reduce Mortality by 50%
September 4, 2012 (Montreal, Quebec) — Regular screening mammography reduces mortality from breast cancer by at least 50% in women 50 to 69 years of age, not by one fifth as estimated by the Canadian Task Force on Preventive Health Care, in the opinion of one public health researcher speaking here at the Union for International Cancer Control World Cancer Congress 2012.
Wilbur Deck, MD, from the National Institute for Excellence in Health and Social Services in Quebec City, Quebec, Canada, took the Canadian Task Force to task for their estimation of the mortality benefit from regular mammography, which he feels is "clearly biased downward" for women 50 to 69 years of age.
In their update of screening recommendations published in 2011, the Canadian Task Force recommends routine screening every 2 to 3 years for women 50 to 69 years of age on the basis of "moderate quality" evidence.
This recommendation is graded as "weak."
"The task force did not do the actual review of the screening studies. They farmed out what I think should be their core competency, which is to analyze the data. It was the group [to whom the review was farmed out] that estimated that the reduction in mortality from breast cancer screening was 21%," Dr. Deck told Medscape Medical News. "Even though a lot of people in those studies were never actually screened, the task force never challenged that number."
As Dr. Deck explained to delegates, there is a large discrepancy between estimates of mortality reduction from mammography, ranging from virtually no benefit to as much as 35%.
Evidence From RCTs
By far the most common evidence used to arrive at these mortality estimates comes from randomized controlled trials (RCTs).
"RCTs show about a 20% mortality reduction [with mammography], but it's important to point out that this estimate is unadjusted for several major factors," Dr. Deck explained.
The first major factor is that some of the studies were initiated in the 1960s, when the technology used to screen for breast cancer was far less advanced than the dedicated mammography equipment used today.
A second is what Dr. Deck called "low contrast" in these screening studies.
"When you do an RCT, you compare those who had a trial intervention to a control group that doesn't get the intervention; in most RCTs, that is approximately true," he said.
However, in breast cancer screening studies, "it is not approximately true because probably less than 50% of participants are getting regular screening," Dr. Deck noted. People in the control group can also decide they might benefit from mammography and go out and get screened, thereby diluting the control group.
"This reduces the contrast [between the 2 groups] and, obviously, it reduces how effective mammography will appear to be," Dr. Deck noted.
The third problem is that breast cancer screening only has an impact over the very long term.
In simulations he himself has done, Dr. Deck calculated that the degree of mortality reduction is underestimated by about half if early mortality data are included in estimates and the data are only followed for about 15 years.
At 10 years, recurrence rates after the initial diagnosis of breast cancer are still high, at approximately 45%, even if a woman has been diagnosed with a small (2 to 3 cm) tumor and only 1 positive node.
In contrast, if a woman has a tumor of 1 to 2 cm and no positive nodes, "the recurrence rate at 10 years is only 17%, so it's pretty important to detect cancer early," Dr. Deck said. Indeed, if stage distribution and prognosis at various stages are used to estimate the mortality reduction from breast cancer related to mammography, "you see reductions of between 50% and 60%," he added.
Similarly, a review of all case–control studies of women who received regular screening and those who did not found a reduction of about 50% in breast cancer mortality with regular screening.
We may be overdoing it in terms of underpromising for mammography.
"It's good to underpromise and overdeliver, but we may be overdoing it in terms of underpromising for mammography," Dr. Deck said. "If you look at RCTs and adjust for participation, contrast, and timing, you arrive at a mortality reduction of 50% to 60%; if you look at stage-distribution estimates, it's about 50% to 60%; and if you look at case–control studies, it's about 50%. These estimates don't take into account probable improvements in mortality based on technological advances. I think groups like the Canadian Task Force are probably doing a disservice to people who are considering whether or not mammography might be useful for them," he explained.
Need to Consider Other Morbidities
Session chair Jean Rousseau, PhD, from the Public Health Institute of Canada, emphasized that older women can have other morbidities that need to be taken into account when considering mammography.
Physicians need to start tailoring screening recommendations to older women on the basis of the presence or absence of potentially important morbidities, he explained. "There are a lot of women in the target age group who are still very healthy and who could benefit from mammography — there is no doubt about this — but women in this age group are more diverse than we tend to think," Dr. Rousseau told Medscape Medical News. "You have to ask if mammography is the most appropriate strategy for women who have important morbidities and we need to consider women more on an individual basis with respect to their needs."
Dr. Deck reports being involved with a breast cancer screening program in Quebec. Dr. Rousseau has disclosed no relevant financial relationships.
Union for International Cancer Control (UICC) World Cancer Congress 2012. Presented August 29, 2012.
Isnin, Jun 11
Mari kita berkongsi imej kanser payudara...
inilah imej kanser payudara Lelaki....
A partially circumscribed retroareolar mass in a male with suspicious microcalcifications; this is known breast cancer.
Male Breast Cancer Imaging Author: Marilyn A Roubidoux, MD; Chief Editor: Eugene C Lin, MD
Overview of Male Breast Cancer
The etiology, diagnosis, and treatment of breast cancer in males is similar to that in females. Unlike breast cancer in females, however, breast cancer in men is rare. Although its frequency has increased in recent decades—particularly in the urban United States, Canada, and the United Kingdom—breast cancer in males accounts for less than 1% of breast cancers. In the United States, males were expected to account for only 1,970 of the estimated 209,060 cases of breast cancer that were predicted to occur in 2010.Unfortunately, this rarity has largely precluded prospective randomized clinical trials. It may also contribute to the infrequency of early diagnosis. Men tend to be diagnosed with breast cancer at an older age than women, and they have proportionately higher mortality, although outcomes for male and female patients with breast cancer are similar when survival is adjusted for age at diagnosis and stage of disease.
Etiology
Environmental and genetic risk factors for male breast cancer have been identified. In approximately 30% of cases, the family history is positive for breast cancer. A familial form of breast cancer is seen in which both sexes are at increased risk for breast cancer. Familial cases usually have BRCA2 rather than BRCA1 mutations. Klinefelter syndrome is the strongest risk factor. Males with the syndrome have a risk of breast cancer that approaches that of females.
Exogenous hormone therapy, such as treatment for prostate cancer, is not associated with an increased risk of male breast tumors; breast masses in these patients are more commonly found to be metastatic disease rather than primary breast cancer. However, an increased risk of breast tumors was found in men exposed to estrogen-containing creams in the soap and perfume industries, as well as in men with testicular injury. Liver cirrhosis, which may be associated with elevated estrogen levels, has been associated with male breast cancer. A few transsexual (male to female) patients have been reported with breast cancer 5-10 years after initiation of estrogen therapy; however, it is not known whether these patients are at an increased risk compared with nontranssexual males.
These epidemiologic factors, in addition to studies suggesting that men with breast cancer have elevated estriol production, indicate a relationship between male breast cancer and hormones.
Diagnosis
Male breast cancer usually presents as a painless lump. In 75% of cases, the lump is a hard and fixed nodule in the subareolar region, with nipple commitment earlier than in women.Often, the disease is not detected until late in its course: more than 40% of patients have stage III or IV disease at diagnosis.
In patients with clinical features completely consistent with gynecomastia, breast cancer may be excluded on clinical grounds, and no further evaluation may be necessary. If findings are equivocal, however, mammography can be useful in diagnosis.
Fine-needle aspiration biopsy can confirm the diagnosis. Histologically, the majority of breast cancers in men are infiltrating ductal carcinomas, but the entire spectrum of histological variants of breast cancer has been seen. Papillary carcinoma is a distant second in frequency. Lobular carcinoma is uncommon.
Treatment & Management
The standard of care for male breast cancer is modified radical mastectomy with sentinel node biopsy. Approximately 90% of these tumors are hormone-receptor positive; consequently, tamoxifen is the standard choice for adjuvant chemotherapy. Indications for radiotherapy are similar to those for female breast cancer (see Breast Cancer, as well as Breast Cancer Screening, Breast Cancer Histology, Adjuvant Therapy in Breast Cancer, and Surgical Treatment of Breast Cancer).
Hormone therapy is the principal treatment for metastatic disease. However, chemotherapy can also provide palliation. Second-line hormonal approaches include orchiectomy, aromatase inhibitors, and androgen ablation.
Long-term monitoring
Men who have had breast cancer are at increased risk for a second ipsilateral or contralateral breast cancer. The risk of subsequent contralateral breast cancer is highest in men who were younger than 50 years when their initial cancer was diagnosed. Thus, periodic screening is probably advisable.
Assallammualaikum dan salam 1Malaysia..bertemu kembali kita di ruangan ini..disini kami akan paparkan satu artikel yang boleh menjadi rujukan untuk kita semua..kiranya inilah artikel yang terbaru yang telah kami perolehi dari Journal yang terpilih....mungkin ianya akan membantu kita semua dalam mencari faktor-faktor risiko penyebab kepada Kanser payudara..
From Medscape Medical News .Oncology
Night Shift Ups Breast Cancer Risk: New Data
Zosia Chustecka
Authors and Disclosures
May 29, 2012 — Another study has shown an association between night-shift work and breast cancer. It was conducted in Danish female military workers; many of the previous studies focused on nurses or other people who do shift work, such as flight attendants.
It showed, for the first time, that women who prefer mornings (so-called "larks") are at greater risk when they work night shifts than women who prefer evenings (so-called "owls").
The results, from an analysis of data on more than 18,551 women, are published online May 28 in Occupational and Environmental Medicine.
"This study supports to the hypothesis that night-shift work increases the risk for breast cancer," say researchers Johnni Hansen, PhD, and Christina Lassen, from the Institute of Cancer Epidemiology, Danish Cancer Society in Copenhagen.
"So far, 10 of 13 epidemiologic studies of night-shift work have shown an increased risk for breast cancer, and about 50 animal studies have shown the same tendency," Dr. Hansen told Medscape Medical News.
It is...too early to state that night-shift work increases the risk for breast cancer, but the evidence is growing.
"It is, however, too early to state that night-shift work increases the risk for breast cancer, but the evidence is growing," he said. There is very little epidemiologic evidence on other types of cancer so far, he added.
The International Agency for Research on Cancer concluded in 2007 that shift work that involves circadian disruption is "probably carcinogenic" to humans. In 2009, Denmark became the first country to pay government compensation to women who developed breast cancer after long spells of working at night.
Study From "Top Notch" Researcher
The current study, from a "top notch" researcher in the field, "comes in a series of mostly supportive studies, none of which can prove cause and effect but together are getting close," said Richard Stevens, PhD, professor of cancer epidemiologist at the University of Connecticut Health Center in Farmington
Dr. Stevens was not involved in the study, but has published on circadian rhythm disruption, specifically on "light at night" increasing the risk for breast cancer.
He explained that this Danish study has 2 features that are new: diurnal preference data and information on sun exposure.
The researchers highlight the diurnal preference data as being a "unique aspect" of their study. In a detailed questionnaire, they asked women whether they had a preference for morning or evening, identifying the women as being either larks or owls.
Other questions covered the major potential confounders of breast cancer, including body mass index, alcohol consumption, menopausal status, use of hormone replacement therapy, use of contraceptives, occupational exposure to radar or electromagnetic fields, age at menarche and menopause, number of childbirths, tobacco use, occasional sun exposure, occupational physical activity, and workload.
Taking these confounders into account "changes the results only marginally," they note.
Overall Doubling of Risk
For their study, the researchers scoured data on 18,551 women who had served in the Danish Army from 1964 to 1999, and identified 218 women who developed breast cancer. They were able to contact 210 of these women, and matched them with 899 control subjects for further study.In total, 141 women with breast cancer and 551 control subjects completed the questionnaire.After adjustment for confounders, the analysis showed that women who worked night shifts at least 3 times a week for at least 6 years were more than twice as likely to have breast cancer as matched control subjects (odds ratio [OR], Working fewer than 2 nights per week did not appear to increase the risk for breast cancer, presumably because there waless disruption of the body clock, the researchers note.
Striking Difference Between Larks and Owls
Among the women who worked more than 3 nights per week for at least 6 years, there was a striking difference between those with a preference for mornings and those with a preference for evenings. The self-identified larks who worked nights had a nearly 4-fold increase in risk for breast cancer, compared with matched control subjects who did not work nights (OR, 3.9); the owls who worked nights had a 2-fold increase in risk for breast cancer, compared with control subjects.However, among women who did not work night shifts, larks tended to have a lower overall risk for breast cancer than owls.This suggests that larks are less tolerant of night-shift work than owls, and that this observation warrants exploration in larger studies, the researchers note.Dr. Hansen told Medscape Medical News that they asked specifically about diurnal preferences because of evidence that it is associated with a differential expression of clock genes.
These clock genes are involved in the regulation of 10% to 20% of the entire genome, and are related to breast cancer risk, he explained. Previous work has suggested that larks are more genetically susceptible to changes in circadian rhythm (consistent with a genetic variant of the PER3 long repeat) that have been associated with an increase in breast cancer risk.
"Our observation is consistent with this," Dr. Hansen noted.
Dr. Stevens highlighted this result, saying that it is consistent with the prediction that morning types who do shift work are at greatest risk.He also highlighted the information on sun exposure. One of the theories put forward to explain this increased risk forbreast cancer is that night-shift workers are less exposed to ultraviolet radiation from the sun (the most important source of vitamin D production), Dr. Hansen said. However, the questionnaire used in this Danish study showed that women who worked at night reported more exposure to sunlight than the women who worked during the day, because they are inside during normal week days, he said.
How Is Cancer Risk Increased?
Several other hypotheses, some partly overlapping, have been put forward to explain how night-shift work increases the risk for breast cancer.Many focus on the exposure to light at night, which decreases the night hormone melatonin that seems to protect against cancer, Dr. Hansen explained. This can also cause circadian disruption, where "the master clock in the brain become desynchronized from local cellular clocks in different organs, including the breast."
"Repeated phase shifting with internal desynchronization may lead to defects in the regulation of the circadian cell cycle, favoring uncontrolled growth," he said.In addition, sleep deprivation after night-shift work leads to suppression of immune surveillance, which might permit the establishment and/or growth of malignant clones," he continued.
"Finally, long-term exposure to light at night may result in epigenetic changes," he said.
Melatonin Has AntiCancer Activity
"This is an excellent paper," said David Blask, MD, PhD, head of chrono-neuroendocrine oncology at Tulane University School of Medicine in New Orleans, Louisiana. It replicates most of the other studies done in this field, and again shows an increased risk for breast cancer related to night shifts.
"I think the evidence is getting stronger that night-shift work is a risk factor for breast cancer, especially with this new study, which is the eleventh to show such an effect," he said. "In science, we draw conclusions on the preponderance of evidence. The total picture is getting stronger and is backed up with the laboratory work that we and others have done," he told Medscape Medical News.
Dr. Blask's team previously showed that melatonin has direct anticancer activity on breast cancer cells, which they proposed as a mechanistic explanation for why shift workers are at increased risk. In a study published several years ago (Cancer Res. 2005;65:11174-11184), his team found that blood samples taken from women at night had high levels of melatonin, which had an marked inhibitory effect on breast cancer cells growing in vitro, whereas blood samples taken from the same women during daylight had much lower levels of melatonin and allowed the tumor cells to proliferate. "These mechanistic studies are the first to provide a rational biological explanation for the increased breast cancer risk in female night-shift workers," the researchers concluded.
The study was supported by a grant from the Danish Ministry of Defence. The authors have disclosed no relevant financial relationships.
Occup Environ Med. Published online May 28, 2012. Abstract
[CLOSE WINDOW]Authors and DisclosuresJournalistZosia ChusteckaZosia Chustecka is the News Editor for Medscape Oncology. A pharmacology graduate based in London, UK, she has edited and written extensively for publications aimed at clinician audiences. Winner of a 2011 Award for Excellence in Urology Health Reporting for an article on prostate cancer, her work also has been recognized by the British Medical Journalists Association, and recently she was awarded a Harvard University Fellowship on Cancer Genetics (May 2011) as well as a US National Press Foundation Cancer Issues Fellowship (October 2010). She can be reached at zchustecka@medscape.net.
Disclosure: Zosia Chustecka has disclosed no relevant financial relationships.
Medscape Medical News © 2012 WebMD, LLC
Selasa, April 10
Assallammualaikum dan salam 1Malaysia....hari ini kita perlu melihat Kehadapan ....Keikhlasan kita dalam melaksanakan apa jua perancangan...dan kata -kata hikmat dari kami...
"Lihatlah di sekeliling kamu dan teguhkan pendirianmu; sepanjang hidup dan usiamu jangan mudah berputus harapan, senyum yang kau berikan dan air mata yang kau titiskan, simpan…jadikan tauladan; segala yang kau pandang dan dengar, simpan…buat pedoman"
....dan bersamalah kita berkongsi keceriaan kami dalam melaksanakan Program Pengesanan Kanser Payudara bersama Pemimpin negara...
Langgan:
Catatan (Atom)